Golden Sun Health Technology Group Ltd. — Form 6-K Summary
Business Context and Reporting Period
The company filed a Form 6-K as a foreign private issuer for February 2024. The report was signed on February 23, 2024, and describes a board appointment rather than operating or financial results.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes
- On February 21, 2024, the board appointed Mr. Xiao Jin as a director, effective immediately.
- Mr. Xiao Jin also joined the audit committee and compensation committee.
- The appointment filled the vacancy created by the resignation of Mr. Wenlong Xia.
- Mr. Xiao Jin has served as Chief Financial Officer of Hebron Technologies Limited since September 2018 and has prior finance and accounting experience in pharmaceutical, engineering, and trading companies.
- The filing states that Mr. Xiao Jin has no family relationship with any director or executive officer and had no reportable transactions with the company during the prior two years under Item 404(a) of Regulation S-K.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, business outlook, risk updates, contingencies, or unusual financial items. It does not disclose the reasons for Mr. Xia’s resignation.
Important Facts to Verify
- Confirm the effective date and scope of Mr. Xiao Jin’s board and committee appointments.
- Review subsequent filings for additional information regarding Mr. Wenlong Xia’s resignation.
- Verify Mr. Xiao Jin’s qualifications and any later changes to the audit and compensation committees.
- Consult the company’s annual report and other filings for financial performance, liquidity, debt, and risk information not included in this Form 6-K.